Corbus Pharmaceuticals Holdings, Inc. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

Corbus Pharmaceuticals Holdings, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $0.00 for the year ending 2022.

  • Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -100.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2021 to 2022.
  • This data is from Corbus Pharmaceuticals Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 7, 2023.
  • XBRL data for this metric is available from 2018 to 2022 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2018 to 2022), Corbus Pharmaceuticals Holdings, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 100.0%.
  • Historical annual values: Fiscal year 2022: $0.00 | Fiscal year 2021: $881.7 thousand | Fiscal year 2020: $3.94 million | Fiscal year 2019: $36.14 million | Fiscal year 2018: $4.82 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: